David Planchard
Villejuif, 94805, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 314 publications
New biomarkers for antibody-drug conjugates in lung cancer the pathologist's perspective.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 15, 2026
Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies.
Journal: The Lancet. Respiratory medicine
Published: May 26, 2026
Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 24, 2026
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: April 15, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received Pembrolizumab.
Journal: JAMA oncology
Published: April 09, 2026
Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: March 12, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.
Journal: Future oncology (London, England)
Published: March 04, 2026
First-Line Integration of Local Ablative Therapy With EGFR Tyrosine Kinase Inhibitors in Advanced EGFR+ NSCLC: A Systematic Review and Meta-Analysis.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 01, 2026
Corrigendum to 'Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLC' [Journal of Thoracic Oncology Volume 20 Issue 12 (2025) 1814-1828].
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 23, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib.
Journal: NPJ precision oncology
Published: February 13, 2026
The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.
Journal: Expert review of anticancer therapy
Published: February 05, 2026
MTAP Loss Is Frequent in Oncogene-Driven NSCLC and May Confer Sensitivity to Combined PRMT5 Inhibitors and Targeted Therapies.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 02, 2026
Last Updated: 09/26/2026